VHZ for diagnosis and treatment of cancer
AssigneeAgency for Science, Technology and Research (A*Star)
InventorQi Zeng
Life of this patent
Estimating the term…
Abstract
We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
Claims7
A method of treatment, or alleviation of invasive or metastatic cancer that overexpresses VHZ (VH-1 like member Z) in an individual, the method comprising detecting overexpression of VHZ in a cell of the individual, and administering an anti-VHZ antibody to the individual if the expression of VHZ is increased relative to a reference level, wherein VHZ is a polypeptide having at least 90% sequence identity to SEQ ID NO:
- 2, wherein the anti-VHZ antibody is capable of binding to VHZ of SEQ ID NO:
- 2 and wherein the invasive or metastatic cancer cell becomes non-invasive or non-metastatic as a result.
A method of treatment, or alleviation of an invasive or metastatic cancer in which VHZ is overexpressed in a subject, the method comprising administering an anti-VHZ antibody to the subject thereby inhibiting the formation of VHZ expressing tumor, wherein VHZ is a polypeptide having at least 90% sequence identity to SEQ ID NO:
- 2, wherein the anti-VHZ antibody is capable of binding to VHZ of SEQ ID NO:
- 2 and wherein the invasive or metastatic cancer cell becomes non-invasive or non-metastatic as a result.
A method of treating an invasive or metastatic cancer that overexpresses VHZ in a patient, the method comprising the steps of:
- (a) detecting increased VHZ expression in a cancer cell;
- and (b) reducing the level of VHZ in the cancer cell by administering an anti-VHZ antibody to the patient, wherein VHZ is a polypeptide having at least 90% sequence identity to SEQ ID NO:
- 2, wherein the anti-VHZ antibody is capable of binding to VHZ of SEQ ID NO:
- 2 and wherein the invasive or metastatic cancer cell becomes non-invasive or non-metastatic as a result.
Dependencies are inferred from the claim text.